Replies to post #22565 on Curative Biotechnology Inc (CUBT)

[Deuces]

I’ll let him know you said it was bogus meanwhile it was a registered company. Lol

[dunwifit]

Nobelpharma changed their name to Nobel Biocare and then reorganized in 2002. The former Japanese subsidiary was spun off and took the name Nobelpharma. Now they are returning to the USA and this is a VERY BIG DEAL!

[Deuces]

Paul M. Michaels, 51, was president of Nobelpharma USA Corp. a wholly owned subsidiary of Nobelpharma Japan. Nobelpharma Japan is a specialty pharmaceutical company, focused solely on Orphan drug development that was formed with the assistance of Mr. Michaels to develop orphan drugs for the Asian market. Initial capital commitments are in excess of $30 million. Nobelpharma’s joint venture partner is Inabata & Co., Ltd, which is a trading company with over $4 billion in annual sales. Prior to being elected as president of Nobelpharma USA, from 2000 until June 2003, Mr. Michaels served as CFO of Inabata America Corp the wholly owned US based subsidiary of Inabata & Co., Ltd. Mr. Michaels joined Inabata America Corp in 1993 and has advised them on numerous licensing transactions, corporate divestitures as well as bridge loans and corporate and technology acquisitions. Mr. Michaels began his career on Wall Street in 1986 and prior to working at Inabata held a series of corporate finance and/or managerial positions in several New York retail, based investment banking firms.

[Deuces]

Licensing activity begins in 1996 with Sumitomo Pharmaceuticals, through the negotiations of Investment Banker, Paul M. Michaels, licenses Ambisome and Danisome for the Asian marketplace from a U.S. Pharmaceutical company. This is the beginning of business licensing U.S. developed drugs for the Japanese market. Additionally, an Orphan drug business is created with the assistance of Paul M. Michaels with his Japanese counterparts called Nobelpharma. Co.Ltd. The first licensed product, from Teva Pharmaceuticals USA, is for the treatment of Wilson's disease in Japan. This transaction was negotiated and completed by Paul Michaels.